Cel-Sci is struggling to commercialize its Multikine cancer therapy; it recently closed on a small but expensive financing. The company has completed its initial end of phase 3 meeting with the FDA; ...

This new Registration Study targets the population of previously untreated resectable stage 3 and 4 head and neck cancer patients who had no lymph node involvement and low PD-L1 tumor expression.

Investigators at Memorial Sloan Kettering Cancer Center (MSK) have published results from a clinical trial that found people with recurrent multiple myeloma may benefit from receiving chimeric antigen ...

The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...

VIENNA, Va., May 19, 2025--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that during its annual Shareholder’s Meeting on May 19, 2025, a combination was authorized for its ...